Learning Objectives:

At the conclusion of the educational presentation, the participant will be able to: 

• • Discuss AE management, patient/care partner education, and therapy sequencing for current and evolving myeloma therapies, including upfront quadruplets, anti-CD-38 antibodies, T-cell engagers (bispecific antibodies), CAR-T cell therapy, autologous stem cell transplantation, SINE inhibitors, CELMoDs, and antibody-drug conjugates.
  • Use tactics to enhance access to therapies and clinical trials, including shared decision-making and best practices for transitions of care between community and academic settings.
  • Explain the importance of deep responses and the role of minimal residual disease (MRD) testing in practical treatment management to achieve improved patient outcomes.
  • Identify disparities faced by patients with multiple myeloma and summarize strategies to promote health equity, clinical trial diversity, and enhanced shared decision making